Evidence map›Paper›PMID 39342612›Full record

Observational studyAsian Pacific journal of cancer prevention : APJCP2024

Correlation of CD 133 Biomarker with Outcomes and Therapy Response in Advanced-Stage Non-Small Cell Lung Carcinoma.

Sri Mayasari, Arif Santoso, Irawaty Djaharuddin, Harun Iskandar, Nurjannah Lihawa, Harry Akza Putrawan, Imam Nurjaya, Rasiha Rasiha

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Asian Pacific journal of cancer prevention : APJCP, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sri MayasariPulmonology and Respiratory Medicine Department, Medical Faculty of Hasanuddin University, Makassar, South Sulawesi, Indonesia.ORCID 0009-0000-5330-0646
Arif SantosoPulmonology and Respiratory Medicine Department, Medical Faculty of Hasanuddin University, Makassar, South Sulawesi, Indonesia.ORCID 0000-0003-4125-005X
Irawaty DjaharuddinPulmonology and Respiratory Medicine Department, Medical Faculty of Hasanuddin University, Makassar, South Sulawesi, Indonesia.ORCID 0000-0002-5240-4950
Harun IskandarPulmonology and Respiratory Medicine Department, Medical Faculty of Hasanuddin University, Makassar, South Sulawesi, Indonesia.ORCID 0000-0002-2424-0178
Nurjannah LihawaPulmonology and Respiratory Medicine Department, Medical Faculty of Hasanuddin University, Makassar, South Sulawesi, Indonesia.ORCID 0000-0003-1778-2507
Harry Akza PutrawanPulmonology and Respiratory Medicine Department, Medical Faculty of Hasanuddin University, Makassar, South Sulawesi, Indonesia.
Imam NurjayaPulmonology and Respiratory Medicine Department, Medical Faculty of Hasanuddin University, Makassar, South Sulawesi, Indonesia.ORCID 0009-0007-3155-1680
Rasiha RasihaPulmonology and Respiratory Medicine Department, Medical Faculty of Hasanuddin University, Makassar, South Sulawesi, Indonesia.ORCID 0000-0002-3944-9556

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed to analyze CD 133 stem cell biomarker levels in serum and bronchial lavage, as well as correlate these levels with treatment responses and outcomes in patients with advanced-stage NSCLC.

methodsThis is a cross-sectional, observational, and analytical study that analyzed data from NSCLC patients and control at Dr. Wahidin Sudirohusodo Hospital, Makassar. CD 133 levels in serum and bronchial lavages were quantified using ELISA and correlated with treatment responses assessed by RECIST 1.1 criteria.

resultA total of 118 participants were used, with 66 being NSCLC patients and 52 as the control. The results showed significant differences in CD 133 serum and bronchial lavage levels (p<0.05). Moreover, NSCLC patients with advanced tumors (T4) had higher CD 133 levels in bronchial wash (p<0.05). The bronchial wash CD 133 test showed higher sensitivity (83.6%) and specificity (79.2%) compared to serum CD 133. Even though CD 133 levels were not significantly correlated with treatment response, they were higher in patients with advanced tumor stages.

conclusionCD 133 levels were significantly higher in bronchial wash samples from NSCLC patients with advanced tumors (T4). Also, there was a positive correlation between CD 133 levels in bronchial wash and serum. These results emphasized the potential of CD 133, particularly in bronchial wash, as a valuable diagnostic tool for NSCLC.

Indexed as

Biomarkers, TumorCarcinoma, Non-Small-Cell LungLung NeoplasmsAC133 AntigenAdultAgedCase-Control StudiesCross-Sectional StudiesFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm StagingPrognosisAC133 AntigenBiomarkers, TumorBronchial lavageCD 133non-small cell lung cancerRECIST

Identifiers

PMID39342612
PMCPMC11700334

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.